Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US ...

Germany stands out within the EU4 and the UK with the highest Bullous Pemphigoid market value, reflecting its central role in the region's treatment landscape. As the market continues to evolve ...

A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the ...

An England-wide study of 331 rare diseases in over 58 million people co-led by UCL researchers has identified eight rare diseases that carry ...

Dupixent continues to be a transformative medicine with over 1 million patients on treatment around the ... in chronic spontaneous urticaria and bullous pemphigoid. Regarding the ongoing launch ...

IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate ... obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic ...